Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 546 results found since Jan 2013.

The role of stem cell factor and granulocyte-colony stimulating factor in treatment of stroke.
This article summarizes the discovery of new routes of treatment for acute and chronic stroke using two hematopoietic growth factors, stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF). In a study of acute stroke, SCF and G-CSF alone or in combination displays neuroprotective effects in an animal model of stroke. SCF appears to be the optimal treatment for acute stroke as the functional outcome is superior to G-CSF alone or in combination (SCF+G-CSF); however, SCF+G-CSF does show better functional recovery than G-CSF. In a chronic stroke study, the therapeutic effects of SCF and G-CSF alone or in comb...
Source: Recent Patents on CNS Drug Discovery - November 20, 2014 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research

Subtype-Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study.
Abstract Volume depletion as an adverse events (AE) caused by sodium-glucose cotransporter-2 inhibitors (SGLT2i) because of their diuretic effect may raise the concern about the risk of lacunar stroke; however, an earlier meta-analysis reported no significant increase in the incidence of stroke without clearly distinguishing stroke subtypes. Here, aiming to investigate subtype-wise reporting of stroke potentially related to SGLT2i treatment, we conducted a disproportionality analysis using the Japanese Adverse Drug Event Report database, which contains approximately 500 000 cases recorded between April 2004 and M...
Source: The Journal of Clinical Pharmacology - December 1, 2019 Category: Drugs & Pharmacology Authors: Sato K, Mano T, Iwata A, Toda T Tags: J Clin Pharmacol Source Type: research

Timing of Initiation of Oral Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation
AbstractPatients with atrial fibrillation (AF) who suffer an acute ischemic stroke are at risk for both hemorrhagic transformation and recurrent ischemic stroke in the acute post ‐stroke period. Oral anticoagulants are recommended for secondary stroke prevention in patients with AF. The optimal time to initiate anticoagulant therapy after acute ischemic stroke in patients with AF is uncertain. There is concern that early initiation increases the risk of hemorrhagic transfo rmation, whereas delayed initiation leaves the patient at risk for recurrent ischemic stroke. In this article, we provide a review of the risk of hemo...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 6, 2019 Category: Drugs & Pharmacology Authors: Maureen A. Smythe, Dennis Parker, Candice L. Garwood, Adam Cuker, Steve R. Mess é Tags: REVIEW OF THERAPEUTICS Source Type: research

Risk of Stroke After Transcatheter Aortic Valve Implantation: Epidemiology, Mechanism, and Management
Conclusions: The overall evidences confirm similar or lower rate of stroke in TAVI versus SAVR. Risk predictors for acute stroke after TAVI are generally related to procedural factors, whereas late stroke is mainly associated with patient characteristics, with a variable impact on cognitive function. The optimal choice for the antithrombotic treatment in TAVI for stroke prevention is yet to be determined. Current data do not support routine use of cerebral embolic protection devices during TAVI.
Source: American Journal of Therapeutics - September 1, 2021 Category: Drugs & Pharmacology Tags: Therapeutic Advances Source Type: research

Network pharmacology and experimental study of phenolic acids in salvia miltiorrhiza bung in preventing ischemic stroke
At present, the preventive effect of ischemic stroke is not ideal, and the preventive drugs are limited. Danshen, the dried root of Salvia miltiorrhiza Bge, is a common medicinal herb in Traditional Chinese Medicine, which has been used for the treatment of cardiovascular diseases for many years. Phenolic Acids extracted from danshen, which showed multiple biological activities, have been developed as an injection for the treatment of ischemic stroke. However, its preventive effect on ischemic stroke has not been fully reported. The current study aimed to identify the potential active phenolic acids for the prevention of i...
Source: Frontiers in Pharmacology - January 27, 2023 Category: Drugs & Pharmacology Source Type: research

Acute antithrombotic treatment of ischemic stroke.
Abstract Antithrombotic medication is a cornerstone of acute ischemic stroke treatment and secondary prevention. The efficacy of thrombolysis with alteplase in acute stroke has been demonstrated in several clinical trials. This safe and costeffective therapy has transformed the practice of stroke care and has led to subsequent trials of other antithrombotic medications for treatment of ischemic stroke in the acute phase. These antithrombotics include thrombolytic, antiplatelet and anticoagulant agents. While, no other medication has yet demonstrated adequate efficacy, our current and evolving understanding of infa...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Alderazi YJ, Grotta JC Tags: Curr Vasc Pharmacol Source Type: research

The Impact of Heart Failure and Left Ventricular Dysfunction in Predicting Stroke, Thromboembolism, and Mortality in Atrial Fibrillation Patients: A Systematic Review.
Abstract PURPOSE: Atrial fibrillation (AF) is commonly associated with structural heart disease. Although heart failure (HF) has been proposed as a risk factor for stroke, the coexistence of the 2 diseases increases disproportionally the risk of thromboembolic events. Our objective was to conduct a systematic review to assess the effect of HF on the end points of stroke, systemic embolism (SE), or mortality in patients with AF. METHODS: A literature search was performed to identify studies that examined stroke/ SE in relation to AF and HF. Overall, 405 articles satisfied the preinclusion criteria. FINDIN...
Source: Clinical Therapeutics - August 18, 2014 Category: Drugs & Pharmacology Authors: Agarwal M, Apostolakis S, Lane DA, Lip GY Tags: Clin Ther Source Type: research

Increasing compliance with national quality measures for stroke through use of a standard order set.
CONCLUSION: A retrospective review of the treatment records of patients hospitalized for acute stroke showed that adherence to national guidelines was increased when providers used a standard order set. PMID: 25991597 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - May 21, 2015 Category: Drugs & Pharmacology Authors: Elder KG, Lemon SK, Costello TJ Tags: Am J Health Syst Pharm Source Type: research

Dl-3-n-Butylphthalide (NBP) ：A Promising Therapeutic Agent for Ischemic Stroke.
Dl-3-n-Butylphthalide (NBP)：A Promising Therapeutic Agent for Ischemic Stroke. CNS Neurol Disord Drug Targets. 2018 Jun 12;: Authors: Wang S, Ma F, Huang LJ, Zhang Y, Peng YC, Xing CH, Feng YP, Wang XL, Peng Y Abstract Stroke is a leading cause of morbidity and mortality in both developed and developing countries all over the world. The only drug for ischemic stroke approved by FDA is recombinant tissue plasminogen activator (rtPA). However, only 2-5% stroke patients receive rtPAs treatment due to its strict therapeutic time window. As ischemic stroke is a complex disease involving in multiple mecha...
Source: CNS and Neurological Disorders Drug Targets - June 12, 2018 Category: Drugs & Pharmacology Authors: Wang S, Ma F, Huang LJ, Zhang Y, Peng YC, Xing CH, Feng YP, Wang XL, Peng Y Tags: CNS Neurol Disord Drug Targets Source Type: research

Ponatinib-induced ischemic stroke in larval zebrafish for drug screening.
In this study, using Ponatinib as an inducer, we developed and characterized a zebrafish ischemic stroke model. This zebrafish ischemic stroke had the cerebral vascular endothelial injury, thrombosis, reduced blood flow, inflammation and apoptosis as well as the reduced motility. The zebrafish ischemic stroke model was validated with 6 known human therapeutic drugs of ischemic stroke (Aspirin, Clopidogrel, Naoxintong capsules, Edaravone, Xingnaojing injection, Shuxuening injection). The mRNA levels of the neovascularization-related gene (vegfaa) and vascular endothelial growth factor receptor gene (VEGFR), neurodevelopment...
Source: European Journal of Pharmacology - July 11, 2020 Category: Drugs & Pharmacology Authors: Zhu XY, Xia B, Ye T, Dai MZ, Yang H, Li CQ, Li P Tags: Eur J Pharmacol Source Type: research

The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke.
Abstract Cerebral ischemia is one of the major causes of disability worldwide. In cerebral ischemic stroke, occlusion of a major cerebral artery by an embolus or local thrombosis can result in transient or permanent reduction of cerebral blood flow to a portion of the brain, resulting in deprivation of glucose and oxygen. Since the brain relies on a continuous supply of nutrients and ions via mostly carrier mediated processes across the blood-brain barrier (BBB), any irregularity in these transport mechanisms dramatically affects neuronal function and outcome after acute and chronic stroke. Despite numerous encour...
Source: Current Pharmaceutical Design - June 19, 2013 Category: Drugs & Pharmacology Authors: Shah K, Abbruscato T Tags: Curr Pharm Des Source Type: research

Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
CONCLUSIONS: It is unlikely that SGLT inhibitors have a positive or negative effect on stroke risk, but the question that remains unanswered is whether SGLT inhibitors can yield a protective effect after acute ischemic stroke. Future observational studies and registries may be the first step to help answer this question. (Clin Ther. 2020; XX:XXX-XXX) © 2020 Elsevier HS Journals, Inc. PMID: 33008610 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - September 28, 2020 Category: Drugs & Pharmacology Authors: Al Hamed FA, Elewa H Tags: Clin Ther Source Type: research

Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke.
Abstract Ischemic stroke is one of the leading causes of severe disability and death. In clinical settings, tissue plasminogen activator (t-PA) for thrombolytic therapy is the only globally approved drug for the treatment of ischemic stroke. However, the proportion of patients who receive t-PA therapy is extremely limited due to its narrow therapeutic time window (TTW) and the risk of cerebral hemorrhage. Cerebral ischemia-reperfusion (I/R) injury is also a serious problem for patients' outcomes. Hence, the development of more effective therapies has been desired to prolong the TTW of t-PA and prevent cerebral I/R...
Source: Biological and Pharmaceutical Bulletin - March 6, 2019 Category: Drugs & Pharmacology Authors: Fukuta T, Ishii T, Asai T, Oku N Tags: Biol Pharm Bull Source Type: research

Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Expert Opin Investig Drugs. 2021 Sep 24. doi: 10.1080/13543784.2021.1985463. Online ahead of print.ABSTRACTINTRODUCTION: Recent years have witnessed unprecedented progress in stroke care, but unmet needs persist regarding the efficacy of acute treatment and secondary prevention. Novel approaches are being tested to enhance the efficacy of thrombolysis or provide neuroprotection in non-thrombolized patients.AREAS COVERED: The current review highlights pharmaceutical agents under evaluation in clinical trials concerning the acute, subacute, and chronic phase post-stroke. We examine the evidence in favor of tenecteplase as an...
Source: Expert Opinion on Investigational Drugs - September 24, 2021 Category: Drugs & Pharmacology Authors: Apostolos Safouris Georgios Magoufis Georgios Tsivgoulis Source Type: research